ArticleFrontiers in endocrinology2025
The relationship between advanced glycation end products, metabolic metrics, HbA
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Potential of circulating miR-29a and miR-142-5p as biomarkers for diabetic nephropathy: a cross-sectional study.Frontiers in medicine · 2026Article
- Gene regulatory networks involved in activation of Notch signaling by AGEs in the pathogenesis of diabetic kidney disease.PloS one · 2026Article
- Bidirectional regulation of liver sinusoidal clearance by amino acid nanofibers and IGFBP4 complex: effects on HbA1c.Journal of nanobiotechnology · 2025Article
- [Elevated advanced glycation endproducts is a risk factor for stenosis after primary arteriovenous fistula surgery].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Triglyceride glucose-body mass index is associated with diabetic kidney disease in type 2 diabetes mellitus patients without non-alcoholic fatty liver disease.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this cross-sectional study, we aim to investigate the value of non-invasive advanced glycation end products (AGEs) detection in the early screening of diabetic nephropathy(DN) among individuals with type 2 diabetes mellitus and assess whether metabolic parameters and glycated hemoglobin A Methods: A total of 912 T2DM patients were enrolled. The urinary albumin-to-creatinine ratio (UACR) was measured in morning urine samples to assess DN. AGEs were non-invasively measured through skin autofluorescence. Recognizing the role of age in both AGEs and DN, AGE Results: The overall prevalence of DN in the present study was 37.2%. Elevated AGE Conclusions: Complex associations and interactions were observed between AGEs, metabolic metrics, HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.